Mylan Inc.
MYL today announced an expanded licensing agreement between Gilead
Sciences Inc. and Mylan's Matrix Laboratories Limited. Matrix has licensed the
rights to produce and market generic versions of three Gilead HIV/AIDS
therapies, if and when they receive regulatory approval.
The Gilead products,
which are currently in late-stage clinical development, include: Elvitegravir,
an investigational integrase inhibitor; Cobicistat, an investigational
antiretroviral boosting agent; and the "Quad," a once-daily,
single-tablet combination of four separate Gilead medicines.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in